To the editor
Novel agents in R/R PTCL
Novel regimens in R/R PTCL
Agent | Target | Phase | Accrual | Major subtype | Median prior therapy | Response | Survival | Major grade 3–4 AEs | Abstract number | References |
---|---|---|---|---|---|---|---|---|---|---|
Valemetostat | EZH1/2 | II | 133 | AITL (31.6%), PTCL-NOS (30.8%), ALK-negative ALCL (5.3%), ALK-positive ALCL (1.5%), PTCL-TFH (6.0%), other (14.3%) | 2 | ORR 43.7%, CR 14.3%, PR 29.4%, mDOR 11.9 m | mPFS 5.5 m, mOS 17.0 m | Thrombocytopenia (23.3%), Anemia (18.8%), Neutropenia (17.3%) | 302 | [3] |
HH2853 | EZH1/2 | Ib | 34 | AITL (41.2%), PTCL-NOS (32.4%), ALK-negative ALCL (11.8%), NKTCL (5.9%), PTCL-TFH (5.9%), SKIN-PTCL (2.9%) | 2 | ORR 60.7%, CR 21.4%, PR 39.3%, SD 14.3%, mDOR not reached | mPFS not reached, 3-m PFS rate 74.44%, mOS not reached, 6-m OS rate 91.97% | Thrombocytopenia (14.7%), Neutrophil count decreased (11.8%) | 304 | [4] |
Golidocitinib | JAK1 | II | 104 | PTCL-NOS (57%), AITL (18%), ALCL (11%), NKTCL (3%) | 2 | ORR 44.3%, CR 24%, PR 20%, SD 19%, mDOR 20.7 m | mPFS 5.6 m, mOS 19.4 m | Neutrophil count decreased (29%), White blood cell count decreased (26%), Lymphocyte count decreased (21%), Thrombocytopenia (20%) | 305 | [5] |
Linperlisib | PI3Kδ | II | 98 | AITL (49%), PTCL-NOS (24%), NKTCL (8%), ALCL (2%) | 2 | ORR 48%, CR 30%, PR 18%, SD 20%, mDOR not reached | mPFS 5.5 m, mOS 14.2 m | Neutropenia (32%), Pneumonia (14%), Leukopenia (10%), Anemia (6%), Thrombocytopenia (5%), Upper respiratory tract infection (5%), Lymphocytopenia (5%) | 306 | [6] |
BR101801 | PI3K γ/δ and DNA-PK | Ib | 26 | PTCL-NOS (42%), AITL (42%) | 2 | ORR 31.6%, CR 21.1%, PR 10.5%, mDOR not reached | mPFS 7.5 m, mOS not reached | AST increased (19.2%), ALT increased (15.4%), Neutropenia (15.4%) | 1701 | [7] |
Lacutamab | KIR3DL2 | Ib | 10 | N/A | 3 | N/A | N/A | Serum sickness (10%), AST increased (10%) | 3072 | [8] |
Regimen | Study type | Accrual | Major subtype | Median prior therapy | Efficacy | Major AEs | Abstract number | References |
---|---|---|---|---|---|---|---|---|
Novel agent + SCT vs. Chemotherapy + SCT vs. Novel agent vs. Chemotherapy | Retrospective | 184 | AITL (28.3%), PTCL-NOS (21.2%), ATLL (8.5%), and ALCL (13%) | N/A | mEFS 16.0 m vs. 15.0 m vs.3.9 m vs. 4.1 m, mOS 70.7 m vs. not reached vs. 23.3 m vs. 16.7 m | N/A | 1698 | [11] |
Lenalidomide maintenance after salvage therapy | Phase II | 58 | AITL (39.7%), PTCL-NOS (25.9%) | N/A | 1-y PFS 49%, mOS 34.1 m | Hematologic toxicities: Neutropenia, Thrombocytopenia; Non-hematologic toxicities: Skin rash (40%), Nausea (35%), Diarrhea (20%) | 3073 | [12] |
Chidamide + Azacitidine | Phase I | 19 | AITL (57.9%), PTCL-NOS (42.1%) | 2 | ORR 56.25%, DCR 75%, mPFS 6.45 m, mOS 17.5 m | Pain at the injection site (75.0%), Neutropenia (56.3%), Erythema at the injection site (50.0%), Nausea (43.8%), Thrombocytopenia (37.5%), Feeble (37.5%), Anemia (31.3%), Diarrhea (31.3%), Neutropenia with fever (25.0%) | 3076 | [13] |
Chidamide + Parsaclisib | Phase Ib/II | 11 | N/A | 2 | CR 55.6% | Neutropenia (36.4%), Leukopenia (9.1%), Elevation of ALT/AST (9.1%), Diarrhea (9.1%) | 3075 | [14] |